Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT06336707 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
- Lead sponsor
- Hansoh BioMedical R&D Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 11, 2024
- Completion date
- April 8, 2028
- Enrollment
- 1,048 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors